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clinical outcome after treatment for SCID & what biomarkers
are predictive of these outcomes.
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Engraftment Syndrome Has Distinct Biology Compared
with Graft Versus Host Disease
Pooja Khandelwal, Sabine Mellor-Heinke, Stella Davies,
Michael Grimley, Jack Bleesing, Michael Jordan, Sonata Jodele,
Rebecca A. Marsh, Parinda A. Mehta, Kasiani Myers,
Najibah Rehman, Kristi Smiley, Joyce Villanueva,
Alexandra Filipovich. Bone Marrow Transplantation and
Immune Deﬁciency, Cincinnati Children's Hospital Medical
Center, Cincinnati, OH
Introduction: The biology of engraftment syndrome (ES) is
poorly understood and the degree of overlap with GVHD is
unclear.
Methods: To better understand ES, plasma cytokine proﬁles
were evaluated in 52 consecutive pediatric allogeneic bone
marrow transplant recipients prior to transplant, on the day
of stem cell infusion and weekly until day+100. Patients were
divided into three groups, those with isolated engraftment
syndrome (n¼4), acute graft versus host disease without
prior ES (n¼12) and with neither engraftment syndrome nor
acute graft versus host disease (n¼32). Cytokine values were
expressed as mean fold increase from pre transplant values.
Results: Median age of recipients was 6.7 years (range 0.6-
19.4). ES was observed a median of 12.5 days (range 11-15)
after transplant, while aGVHD was diagnosed at median of
55 days (range 19-95 days) after transplant. MCP-1 and
MIP1b were signiﬁcantly elevated in patients with ES during
the ﬁrst two weeks, while remaining unchanged or reduced
in either of the other 2 cohorts. Moreover, while various
cytokines were found to be elevated in patients who devel-
oped aGVHD, the degree of elevation was signiﬁcantly
exaggerated in patients with isolated ES during 4 weeks
post-transplant. (See table 1)
Conclusion: MCP-1 and MIP1b are elevated speciﬁcally in ES
suggesting a separate biology from GVHD. In addition, the
degreeofelevationofpro-inﬂammatorycytokines ismarkedly
greater in children with ES compared to those with GVHD.
Figure 1. MIP1bandMCP1 inpatientswithES, aGVHDandneitherGVHDnorES.Table 1
Cytokine proﬁles in ES, aGVHD and patients with neither ES nor GVHD at 4
weeks after transplant
Cytokine Neither ES nor
GVHD (Mean
fold increase
from pre
transplant
value)
GVHD (Mean
fold increase
from pre
transplant
values)
ES (Mean fold
increase from
pre transplant
values)
P-value
(ES vs
GVHD)
IL1b 0 2 36 <.01
IL4 2 5 40 <.001
IL7 8 6 138 <.01
IL12 14 4.6 108 <.01
IL13 2.8 3 62 <.0195
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Matched related hemopoietic stem cell transplantation
(MRD-HSCT) for patients with Primary Immunodeﬁciencies
(PIDs) has been life saving. There is less information regarding
stem cell transplantation from unrelated donors including
umbilical cord blood units. We report the outcome following
HSCT (1998-2012) in 69 patients with PIDs: SCID (n¼35),WAS
(n¼9), Phagocytic disorders (CGD (n¼17), LAD (n¼4)); and
other (n¼4; one each; Interferon g receptor deﬁciency, Hyper
IgM syndrome, Autosomal recessive Hyper IgE syndrome
(Dock 8 mutation), and reticular dysgenesis). The median age
at transplant was 1 year (range, 0.1-17 years). Twenty patients
received an MRD graft, 22 patients received a matched unre-
lated donor graft (MUD), 4 patients received a mismatched
unrelated donor graft, 15 patients received a haploidentical
related donor graft and 9 patients received a mismatched
unrelated cord blood unit (MMUCB). One patient received
a MMUCB after a haploidentical graft failure. 58 patients
received ablative conditioning regimen with busulfan, cyclo-
phosphamide, and ﬂudarabine or cytarabine. Six patients
received reduced intensity conditioning using ﬂudarabine
with anti-CD52 or/and anti-CD45. Six SCID patients were not
conditioned. 52 patients received anti-CD52; no serotherapy
was given forMMUCB grafts. Graft versus host disease (GvHD)
prophylaxis combined cyclosporine and methotrexate or
cyclosporine and prednisone except for MUCB recipients who
were given cyclosporine and MMF as prophylaxis. Engraft-
ment: Forty ﬁve of 67 evaluable patients (65%) achieved full
donor chimerism (>90%) of all cell lineages including T cells.
Twelve patients had primary graft failure. 10 were hap-
loidentical grafts and 2 were MUD grafts. All except one were
rescued with a repeat stem cell infusion. Just 3/67 patients
developedgrade II-IVaGvHDandnopatientdevelopedchronic
GvHD. Survival.With amedian followupof 4 years (range, 0.3-
12 years), overall survival was: 95% and 86%, for phagocytic
disordersandSCIDs respectively; and77%and75% forWASand
other diseases, respectively. Recipients of MRD and UCB had
100% survival:MUDgraft recipients had an 88% survival, while
recipients of mismatched unrelated or haploidentical related
transplants, had 50% and 71% survival respectively. Infection
was the commonest cause of death. Hence excellent overall
survival for PID patientsmay be obtained after unrelated HSCT
and results usingmatched related grafts andmismatched cord
blood units are highly comparable.96
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Abstracts / Biol Blood Marrow Transplant 19 (2013) S150eS166 S163There is limited data on the prevalence, clinical proﬁle
and outcome of patients with b thalassemia major (TM) who
was HCV sero-positive (HCV+) prior to an allogeneic stem cell
transplant (SCT). From October, 1991 to June, 2012, 370 SCT
were done for TM at our center. Themedian agewas 7.5 years
(range: 2-24) and therewere 232 (62.87%)males. 209 (56.5%)
belonged to Lucarelli Class III. There were 44 (11.9%) cases
who were HCV+, 6 (1.6%) who were HBsAg positive and 350
(94.6%) who were CMV sero-positive at the time of pre-
transplant screening.
HCV+ cases were signiﬁcantly older (P ¼ .000) and had
a signiﬁcantly larger liver size (P ¼ .001). There were signif-
icantly more number of HCV+ cases who were Lucarelli Class
III (84% Vs. 52.8%; P ¼ .000). The number of graft rejections
was signiﬁcantly higher in the HCV+ group (22.7% Vs. 10.4%;
P ¼ .025) while the treatment related mortality was
comparable between the two groups. It is well recognized
that patients with TM are at a high risk of developing sinu-
soidal obstruction syndrome (SOS) post SCT. In this series,
165 (44.6%) patients developed SOS. HCV+ cases did not have
a signiﬁcantly higher incidence of SOS compared to those
that were HCV negative (47.7% Vs. 44.3%; P ¼ .747). Among
the 15 (34%) of HCV+ cases that died, the major contributory
cause of death was infection (40%), graft failure (20%) and
SOS (20%). The overall and event free survival among those
that were HCV+ve Vs. those that were negative was
63.78.1% Vs. 752.5% and 47.48.1% Vs. 702.7%; P-val-
ue¼0.158 and 0.019 respectively. On a univariate cox
regression analysis, HCV+ had an adverse impact on EFS
(RR¼1.710; 95%CI 1.066-1.744; P ¼ .026). However, on
a forward stepwise multivariate analysis after adjusting for
conventional risk factors HCV+ status did not confer an
independent adverse risk factor. Of the 29 HCV+ patients
who are surviving, at a median follow up of 25 months, none
have had progression to chronic liver disease. 20 (69%) had
a normal liver function test at last follow up while only 3
have had HCV directed therapy post transplant.
From August, 2009 at our center we have been using
a treosulfan based conditioning regimen for our Class III
patients. Among the 44 HCV+ patients 10 were conditioned
with this regimen. This regimen was well tolerated with
100% engraftment. Two patients died, one due to sepsis and
the other to GVHD. This compared favorably with the
historical control of HCV+ cases conditioned with a conven-
tional busulfan based regimen.
In conclusion HCV+ status is a surrogate risk factor for
other adverse risk factors such as older age, increased liver
size and inadequate medical therapy prior to SCT. After
adjusting for such risk factors HCV+ cases with TM under-
going an allogeneic SCT transplant have comparable
outcomes to HCV negative cases. Use of a treosulfan based
regimen is well tolerated in the HCV+ group and could
potentially improve the outcome in this high risk group.97
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Juvenile myelomonocytic leukemia (JMML) is a rare and
aggressive childhood haematological malignant disorder.
Allogeneic HSCT is the only proven curative therapy. This
study reports more than 20 years (1986-2011) of French
experience in HSCT for children with JMML.
Outcome of 107 HSCT (91 children) performed between
March 1986 and November 2011 in 18 French centres was
retrospectively studied. Overall Survival (OS), Non Relapse
Mortality (NRM), Graft Versus Host Disease (GVHD) and
relapse cumulative incidences were analyzed per patient
from the ﬁrst transplantation. Multivariate analyses were
performed to assess risk factors. Statistical analyses were
carried out according to guidelines of European group for
Blood and Marrow Transplantation (EBMT).
Ninety-one children (58males), median age 1.4 yrs (range
0.0-15,7 yrs) with JMML underwent 107 allogeneic HSCT (14
second graft and a third one). The median follow-up was 47
months (1-166). At 72 months, OS was 59% (95% CI: 47-74).
Cumulative incidence of aGVHDwas 48% (95% CI: 37-58). The
6-year cumulative incidence of relapse and NRM was 34%
(95% CI: 23-44) and 21% (95% CI: 13-32), respectively. The
median delay of relapse was 80 days (range 15-1096). In
multivariate analysis, age at HSCT older than 2 years, female
donor tomale recipient sex-mismatch, matched unrelated or
mismatched non cord donor, total body irradiation and no
serotherapy in conditioning regimen predicted poorer
outcomes. Age at HSCT older than 2 years was an increased
risk of relapse whereas Busulfan/Cyclophosphamide/
Melphalan conditioning regimen was a decreased risk.
Serotherapy was associated with a decreased risk of NRM.
Age at HSCT older than 2 years and male recipient were
associated with higher probability of dying of NRM causes.
Our results show that allogeneic HSCT may cure approx-
imately 60% of patients with JMML and are similar to best
results published by other groups. Relapse represents the
main cause of treatment failure and a second HSCT should be
proposed. Novel strategies to decrease the risk of relapse are
needed.98
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The presence of acute leukemia or advanced myelodys-
plastic syndrome (MDS with 5% blasts or more) in Fanconi
Anemia (FA) patients is associated with very poor prognosis.
The experience of hematopoietic cell transplantation (HCT)
in these patients is limited, and the question of pre-trans-
plant chemotherapy remains. We report 21 FA patients with
acute myeloid leukemia, acute lymphoblastic leukemia, or
advanced MDS who underwent HCT at the University of
Minnesota from 1988-2009. 6 patients had biallelic BRCA2
mutations (29%). Median age at transplant was 15.5 years
(range 1.1-48.5). 7 patients (33%) received chemotherapy
before HCT, with 4 achieving complete remission. HCT
